SCHEMBL24896308

SCHEMBL24896308

Cn1c(C(=O)O)cc2ccnc(C3CC3)c21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 4/20 0.41
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
HPGD P15428 3/20 0.39
HSD17B10 Q99714 3/20 0.39
GPR35 Q9HC97 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
KDM4C Q9H3R0 3/20 0.36
KDM4A O75164 2/20 0.36
KDM2B Q8NHM5 2/20 0.35
KDM5A P29375 2/20 0.35
KDM5B Q9UGL1 2/20 0.35
SRD5A2 P31213 2/20 0.34
PDE10A Q9Y233 1/20 0.33
MAPK7 Q13164 1/20 0.33
CCNA2 P20248 1/20 0.33
CDK2 P24941 1/20 0.33
TTK P33981 1/20 0.33
SRD5A1 P18405 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30220538 0.82 DHODH (0.40) KDM4EALDH1A1HSD17B10SMN1; SMN2
SCHEMBL24896374 0.78 MCL1 (0.46) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24896384 0.78 GRM4 (0.37)
SCHEMBL24896464 0.77 KDM4E (0.39) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL25003320 0.77 ALDH1A1 (0.35) KDM4EALDH1A1HPGDHSD17B10SMN1; SMN2
SCHEMBL20504453 0.77 MCL1 (0.45) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24896309 0.76 CCNA2 (0.33) CCNA2CDK2TTK
SCHEMBL24896576 0.74 MCL1 (0.43) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24896316 0.74 MCL1 (0.43) MCL1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL24896258 0.74 KDM4E (0.50) MCL1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4370207-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS Nido Biosciences, Inc. (US) 2024-05-22 EP disclosed
US-20230039586-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. 2023-02-09 US disclosed
WO-2023287704-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. (US) 2023-01-19 WO disclosed
WO-2023287704-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS NIDO BIOSCIENCES, INC. (US) 2023-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039586-A1 BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS AR, FSHR, NR5A1 MCL1 4696/4885KDM4E 1723/4885ALDH1A1 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.